News

HOLKIRA PAK is an all-oral, short-course interferon-free treatment, with or without ribavirin (RBV) for the treatment of genotype 1 hepatitis C patients in Canada. The approval follows six

The FDA Orphan Drug Designation program grants a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect less

Under the terms of agreement, Ariad will lead the completion of the Japanese new drug application (NDA) for Iclusig, while Otsuka will file the NDA for regulatory approval

The grant award will assist with advancing an SVP cancer immunotherapy from preclinical through early clinical evaluation. This immuno-oncology program is designed to develop novel SVP immunotherapies capable

With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use. GRANIX, a leukocyte growth

By using real-world evidence, the two parties will focus on developing answers to commonly asked clinical questions about the continuum of diabetes care, such as the role and

The approval was based by data from over 2,700 subjects treated with peramivir in 27 clinical trials. University of Alabama Dr Richard Whitley said: "RAPIVAB is the first

Opdivo is a human programed death receptor-1 (PD-1) blocking antibody indicated to treat this skin cancer. The indication is approved under accelerated approval based on tumor response rate

This patent includes AC-201 or its pharmaceutically acceptable salts, active metabolite for treatment of type II diabetes. The patent also covers the methods of treatment using AC-201 for